Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study
Annals of Clinical and Translational Neurology · 2023-10 · 10 (10) · 1768-1775
DOI: 10.1002/acn3.51865 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 06.08.2023. Verfasst von Stefan Macher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hashimoto Disease, Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Assessing severity of antibody‐mediated encephalitis (AE) or paraneoplastic encephalitis (PE) requires valid and reliable scores to guide treatment decisions and predict outcome both in clinical routine and studies. We aimed to validate the prognostic value of the clinical assessment scale in autoimmune encephalitis (CASE) and the anti‐NMDAR‐encephalitis one‐year functional status (NEOS) score in patients suffering from AE and PE in a large monocentric cohort.
Methods
We retrospectively applied the CASE and NEOS score to patients with definite AE and PE treated at a tertiary hospital. Correlations were established between the CASE and NEOS score and the modified Rankin scale (mRs). Multivariable analyses were calculated to identify predictors of outcome.
Results
Thirty‐four patients (27 AE, 7 PE) were included. Correlations between mRS and CASE score were strongest in patients with AE compared to PE at all intervals, but in the subgroups (LGI1, NMDAR, GAD, miscellaneous surface antibodies, PE) the correlation was strongest in the interval after baseline. Patients with AE seemed to display better outcomes compared to PE, which was underlined by multivariable analysis. Improvement was mostly observed within 6–12 months after disease onset, after which little or no further improvement was noted with some exception for two patients with anti‐NMDARE who recovered substantially even after 12 months of treatment. The NEOS score significantly predicted the outcome at last follow‐up in patients with AE with a sensitivity of 79% at a cut‐off value of 2 points (AUC 0.79, 95% CI 0.58–0.99, p = 0.04).
Interpretation
The CASE and NEOS score are suitable supplementary tools in addition to the mRS for capturing diverse symptoms, for grading and monitoring symptom severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria.
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Stefan Macher, Gabriel Bsteh, Romana Höftberger, Tobias Zrzavy
Zitieren
APA
Macher, S., Bsteh, G., Höftberger, R., Berger, T., Rommer, P., & Zrzavy, T. (2023). Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study. Annals of Clinical and Translational Neurology, 10(10), 1768-1775. https://doi.org/10.1002/acn3.51865
Vancouver
Macher S, Bsteh G, Höftberger R, Berger T, Rommer P, Zrzavy T. Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study. Annals of Clinical and Translational Neurology. 2023;10(10):1768-1775. doi:10.1002/acn3.51865
BibTeX
@article{Macher2023,
author = {Macher, Stefan and Bsteh, Gabriel and Höftberger, Romana and Berger, Thomas and Rommer, Paulus and Zrzavy, Tobias},
title = {Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {10},
pages = {1768--1775},
doi = {10.1002/acn3.51865}
}
EUVIMED